ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ASCO '23 Entrees"
Episode Synopsis
We highlight notable data from this month's ASCO annual meeting.
1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC
2. ADAURA OS results and low rate of osimertinib use in control arm
3. Keynote 671: perioperative pembrolizumab in NSCLC
4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer?
5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+)
6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease)
7. CARTITUDE-4: Cilta-Cel earlier in MM treatment
1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC
2. ADAURA OS results and low rate of osimertinib use in control arm
3. Keynote 671: perioperative pembrolizumab in NSCLC
4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer?
5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+)
6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease)
7. CARTITUDE-4: Cilta-Cel earlier in MM treatment
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust